New PLATO Sub-Analysis of CABG Patients Presented at ACC

Tuesday, 16 March 2010

In this study, 48% fewer deaths reported among heart bypass patients taking BRILINTA (ticagrelor) as compared to clopidogrel

AstraZeneca today announced results of a new analysis of the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study which showed there were fewer deaths in patients with acute coronary syndromes (ACS) who took the investigational oral antiplatelet BRILINTA (ticagrelor) within seven days prior to having heart bypass surgery (coronary artery bypass graft, CABG) compared to those who took clopidogrel. These data were presented today at the American College of Cardiology (ACC) meeting in Atlanta, Georgia.

“The CABG sub-analysis represents current clinical management of patients with ACS,” said Dr Claes Held, PhD, Associate Professor of Cardiology at the Uppsala Clinical Research Center and Department of Cardiology, and the sub-study’s lead researcher. “The effects of ticagrelor compared to clopidogrel showed a reduction of total mortality by 51% and CV death by 48%.”

This analysis included 1261 patients who were on study medication up to seven days prior to stopping study medication due to the need for urgent CABG surgery at any time after their ACS event. The patients randomised to ticagrelor had a significantly lower rate of total and CV death than those randomised to clopidogrel treatment:

  • Total mortality was reduced by 51% (RRR; p<0.01) with ticagrelor (4.6% of 632) compared to clopidogrel (9.2% of 629)
  • CV death was reduced by 48% (RRR; p<0.01) with ticagrelor (4.0% of 632) compared to clopidogrel (7.5% of 629)
  • Rate of the primary endpoint (composite of CV death, myocardial infarction, or stroke) from the time of CABG was 10.5% (66/632) with ticagrelor and 12.6% (79/629) with clopidogrel (HR 0.84; CI 0.60-1.16, p=0.29)

Additionally, there was no significant difference in CABG-related major bleeding for ticagrelor compared to clopidogrel, according to both the PLATO and TIMI bleeding criteria respectively (81% for ticagrelor vs. 80% for clopidogrel, and 59% for ticagrelor vs. 58% for clopidogrel for PLATO-defined and TIMI-defined, respectively).

“These treatment comparisons were consistent with the effects seen in the overall PLATO trial,” said Dr Claes Held.


About CABG (Coronary Artery Bypass Grafting)
CABG surgery is advised for certain ACS patients, including those who are not candidates for percutaneous coronary intervention (PCI). It is not always known which ACS patients will be advised for CABG surgery at the time of initiating oral antiplatelet therapy. These patients have significant narrowing and blockages of the heart arteries (coronary artery disease). CABG is a type of heart surgery that reroutes, or "bypasses," blood around clogged arteries to improve blood flow and oxygen to the heart.

About PLATO CABG analysis
In the PLATO study, a double-dummy, double-blind randomized trial comparing ticagrelor plus aspirin with clopidogrel plus aspirin in patients with ACS, 1899 patients underwent CABG during the trial. The trial recommended administration of ticagrelor/placebo-clopidogrel to be withheld for 24-72 hours and clopidogrel/placebo-ticagrelor for 5 days prior to CABG surgery. In the exploratory analysis, 1261 patients received study-drug up to seven days prior to CABG surgery. The analysis counted events occurring from after the CABG procedure until the end of the study.

Primary results from PLATO were presented at the European Society of Cardiology and simultaneously published in The New England Journal of Medicine in August 2009.

BRILINTA (ticagrelor) is an investigational oral antiplatelet treatment for ACS. Ticagrelor, a cyclo-pentyl-triazolo-pyrimidines (CPTP), is in a chemical class of anti-platelet agents that works differently than thienopyridines, such as clopidogrel and prasugrel, by binding reversibly to the P2Y12 receptor. Ticagrelor is the first reversibly binding oral ADP receptor antagonist.

Ticagrelor is currently under regulatory review in the US and in Europe. BRILIQUE is the approved trade name for use in the EU countries and EEA countries. BRILINTA and BRILIQUE are trademarks of the AstraZeneca group of companies.

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit:


Media Enquiries:
Neil McCrae +44 20 7304 5045 (24 hours)
Chris Sampson +44 20 7304 5130 (24 hours)
Sarah Lindgreen +44 20 7304 5033 (24 hours)
Abigail Baron +44 20 7304 5034 (24 hours)

Investor Enquiries UK:
Jonathan Hunt +44 207 304 5087 mob: +44 7775 704032
Karl Hard +44 207 304 5322 mob: +44 7789 654364
Clive Morris +44 207 304 5084 mob: +44 7710 031012

Investor Enquiries US:
Ed Seage +1 302 886 4065 mob: +1 302 373 1361
Jorgen Winroth +1 212 579 0506 mob: +1 917 612 4043


  • Corporate and financial
  • Science